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Distal enhancers characterized by the H3K4me1
mark play critical roles in developmental and tran-
scriptional programs. However, potential roles of
specific distal regulatory elements in regulating
RNA polymerase II (Pol II) promoter-proximal pause
release remain poorly investigated. Here, we report
that a unique cohort of jumonji C-domain-containing
protein 6 (JMJD6) and bromodomain-containing pro-
tein 4 (Brd4) cobound distal enhancers, termed anti-
pause enhancers (A-PEs), regulate promoter-prox-
imal pause release of a large subset of transcription
units via long-range interactions. Brd4-dependent
JMJD6 recruitment on A-PEs mediates erasure of
H4R3me2(s), which is directly read by 7SK snRNA,
and decapping/demethylation of 7SK snRNA,
ensuring the dismissal of the 7SK snRNA/HEXIM
inhibitory complex. The interactions of both JMJD6
and Brd4 with the P-TEFb complex permit its acti-
vation and pause release of regulated coding genes.
The functions of JMJD6/ Brd4-associated dual
histone and RNA demethylase activity on anti-pause
enhancers have intriguing implications for these pro-
teins in development, homeostasis, and disease.INTRODUCTION
The critical roles of enhancers have been recognized for more
than 25 years, and recently the H3K4me1 mark was identified
to characterize many gene enhancers (Heintzman et al., 2009).
These enhancers have been recently found to be usually associ-
ated with noncoding RNA transcripts called enhancer RNA (Hah
et al., 2013; Lam et al., 2013; Li et al., 2013; Natoli and Andrau,C
2012; Ren, 2010). The molecular mechanisms underlying tran-
scription regulation by enhancers as well as other distal regula-
tory elements with enhancer-like properties remain incompletely
understood.
JMJD6, also known as PTDSR or PSR, a JmjC-domain-
containing protein, has been suggested to possess novel, unex-
pected nuclear functions (Cui et al., 2004; Tibrewal et al., 2007).
Ablation of JMJD6 in mice caused abnormal development and
led to neonatal lethality (Böse et al., 2004; Kunisaki et al.,
2004; Li et al., 2003). It was originally identified as a phosphati-
dylserine receptor on the surface of phagocytes (Fadok et al.,
2000). It has been recently reported to be an arginine demethy-
lase and lysyl-5-hydroxylase (Chang et al., 2007; Webby et al.,
2009), although the potential functional importance of these
activities remains unclear. Meanwhile, a structural study sug-
gested that methyl groups on single-stranded RNAs (ssRNAs)
might be substrates of JMJD6 (Hong et al., 2010).
Brd4, along with Brd2, Brd3, and testes/oocyte-specific BrdT,
comprises the BET domain family of proteins in mammals, which
is characterized by the presence of tandem, amino-terminal
bromodomains and an extraterminal (ET) domain. Knockout of
Brd4 and Brd2 in mice leads to early embryonic lethality (Gyuris
et al., 2009; Houzelstein et al., 2002). Small-molecule inhibition of
Brd4 has been proposed as a promising therapeutic strategy for
certain cancers (Delmore et al., 2011; Filippakopoulos et al.,
2010; Nicodeme et al., 2010; Zuber et al., 2011). Brd4 has
been found in several complexes, including the mediator and
P-TEFb complexes (Jang et al., 2005; Wu et al., 2003; Yang
et al., 2005). The P-TEFb complex is a heterodimer consisting
of the cyclin-dependent kinase Cdk9 and a cyclin component
(Cyclin T1, T2, or K). Brd4 is capable of releasing the P-TEFb
complex from the inhibitory factors, HEXIM1/2 and 7SK snRNA,
through its direct interaction with Cyclin T1, resulting in the
transition of the P-TEFb complex from its inactive to an active
form and subsequent phosphorylation of RNA Pol II, leading to
efficient transcriptional elongation (Jang et al., 2005; Yang
et al., 2005). This positive regulation of the P-TEFb complex isell 155, 1581–1595, December 19, 2013 ª2013 Elsevier Inc. 1581
believed to be vital for Brd4 function (Dey et al., 2009; Har-
greaves et al., 2009; Mochizuki et al., 2008; Yang et al., 2008).
Enhancer-bound Brd4 regulation of transcription has been
recently shown in cancer cells as well as heart failure, although
the underlying molecular mechanisms are incompletely under-
stood (Anand et al., 2013; Lovén et al., 2013).
Emerging evidence suggests that promoter-proximal pausing
of Pol II is a critical regulatory event subsequent to Pol II initiation
on a large set of genes (Adelman and Lis, 2012). Pol II promoter-
proximal pause release is achieved mainly through the action of
the P-TEFb complex, which phosphorylates at least three tar-
gets including the NelfE subunit of NELF, the Spt5 subunit of
DSIF, and serine 2 of RNA Pol II carboxyl-terminal domain
(CTD) (Kim and Sharp, 2001; Marshall et al., 1996; Wada et al.,
1998; Yamada et al., 2006). Half of the total P-TEFb in the cells
is reversibly bound to the inhibitory subunit composed of 7SK
snRNA and HEXIM1/2 and thus is in an inactive form (Nguyen
et al., 2001; Yang et al., 2001), whereas the remaining half asso-
ciates with Brd4 (Jang et al., 2005; Yang et al., 2005). Although
HIV-1 Tat and Brd4 are capable of directly extracting P-TEFb
out from its 7SK snRNP inhibitory complex (Krueger et al.,
2010), the physiological molecular mechanisms governing the
release of P-TEFb complex and transition to the active form
remain incompletely understood.
In the present study, we provide evidence that JMJD6 and
Brd4 physically and functionally interact in the context of the
active P-TEFb complex to regulate Pol II promoter-proximal
pause release of a large cohort of genes. The pause release func-
tion of the JMJD6 and Brd4 complex on these genes is estab-
lished primarily based on binding to distal enhancers, which
we term as anti-pause enhancers (A-PEs). Mechanistically,
7SK snRNA is found to function as a ‘‘reader’’ for H4R3me2(s),
a repressive histone mark, and JMJD6 displays dual demethy-
lase activities toward both H4R3me2(s) and the methyl-cap of
7SK snRNA, resulting in the disassembly of the 7SK snRNA/
HEXIM1 inhibitory complex imposed on the P-TEFb complex.
Simultaneously, both JMJD6 and Brd4 are capable of retaining
the P-TEFb complex through physical interaction with CDK9
and Cyclin T1, respectively, leading to its activation, and eventu-
ating in transcriptional pause release and gene activation.
RESULTS
Physical and Functional Interaction between JMJD6 and
Brd4
Initially, identifying JMJD6 interacting partners in HEK293 cell
lines revealed the presence of Brd4, with six peptides predicted
with high confidence (Figure 1A and Table S1 available online),
consistent with previous reports (Rahman et al., 2011; Webby
et al., 2009). Accordingly, JMJD6 was found in the list of Brd4-
associated proteins, with four peptides predicted with high
confidence, strengthening the possibility that these two proteins
might function together to regulate cellular process (Figure S1A).
In addition, known functional partners of Brd4 were also suc-
cessfully identified in our pull-down, including the P-TEFb
complex composed of Cdk9 and Cyclin T1 (Jang et al., 2005;
Rahman et al., 2011). The interaction between JMJD6 and
Brd4 or P-TEFb complex, including Cdk9 and Cyclin T1/2, was1582 Cell 155, 1581–1595, December 19, 2013 ª2013 Elsevier Inc.further confirmed, suggesting that it associates with the active
form of P-TEFb complex (Figure 1B). To test whether JMJD6
also associates with the inactive form of the P-TEFb complex,
proteins associated with 7SK snRNA were identified. Known
7SK snRNA-associated proteins, including HEXIM1, BCDIN3,
LARP7, and the P-TEFb complex (Cdk9 and Cyclin T1), were
successfully identified, whereas neither JMJD6 nor Brd4 was
detected (Table S2), as further confirmed through immunoblot-
ting (Figure 1C). These data suggest that JMJD6 and Brd4 spe-
cifically interact with the active form of the P-TEFb complex.
Direct interaction between JMJD6 and Brd4 was de-
monstrated in vitro (Figures 1D and S1B) and in HEK293T cells
cotransfected with JMJD6 and Brd4 (Figure 1E). The JMJD6
interacting domain in Brd4 was mapped to a fragment harboring
the extraterminal domain (ET) (aa 471–730) in vitro (Figures S1C–
S1E) and in HEK293T cells (Figure S1F). Similarly, the amino-
terminal and JmjC domains of JMJD6 together mediated its
interaction with Brd4 both in vitro (Figures S1G–S1L) and in
HEK293T cells (Figure S1M).
To begin to examine the transcriptional regulation by
JMJD6 and Brd4 in the context of active P-TEFb complex,
HEK293T cells were transfected with control small interfering
RNA (siRNA) or two independent siRNAs specifically targeting
JMJD6 or Brd4 followed by Gro-seq analyses (Figures 1F,
S2A, and S2B). Each of the two siRNAs targeting JMJD6 or
Brd4 caused transcriptional changes in a substantial number
of genes (Figures 1G, 1H, S2C, and S2D). We subsequently
focused on the conserved program (Figures 1G and 1H). In
accord with their association with the active P-TEFb complex,
82% of JMJD6- or 71% Brd4-regulated genes exhibited
impaired transcription when knocking down of JMJD6 or Brd4,
respectively (Figures 1G and 1H). Significantly, over 56% or
47% of the genes regulated by JMJD6 or Brd4, respectively,
were jointly regulated by these two proteins (n = 1,201) (Figure 1I
and Table S3), 96.2% of which were regulated in the same direc-
tion by both proteins (n = 1,155) (Figure 1J). Out of these 1,155
genes, 88% of them required both JMJD6 and Brd4 for tran-
scriptional activation (n = 1,022) (Figure 1J), as further validated
by quantitative RT-PCR (qRT-PCR) (Figure S2E). These genes
that were positively regulated in common by both JMJD6 and
Brd4 (n = 1,022) were referred to as JB genes. Gene ontology
analysis revealed that functional terms, including cellular meta-
bolic process, embryonic development, RNA splicing and pro-
cessing, cell death and apoptosis, cellular localization, and
cell-cycle regulation, were enriched (Table S4). Together, our
experiments argue in favor of a physical and functional interac-
tion between JMJD6 and Brd4.
Regulation of Pol II Promoter-Proximal Pause Release
by JMJD6 and Brd4
Brd4 has been shown to be critical for transcriptional elongation
presumably through its recruitment of P-TEFb complex. Based
on the fact that JMJD6 andBrd4 coregulated a significant subset
of genes, we hypothesized that JMJD6 might also play a role
in the process of P-TEFb activation and promoter-proximal Pol
II pause release. To test this hypothesis, Pol II chromatin immu-
noprecipitation sequencing (ChIP-seq) analysis was performed
in control siRNA or siRNA specifically targeting JMJD6- or
Figure 1. Physical Interaction between JMJD6 and Brd4 in the Context of Active P-TEFb Complex
(A) JMJD6-associated proteins were purified using Flag-affinity agarose, separated by SDS-PAGE gel, stained with Coomassie blue, and then subjected tomass
spectrometry analysis. Identified peptides for Brd4 were shown on the right.
(B) Nuclear extracts purified from HEK293T cells were subjected to immunoprecipitation (IP) and followed by immunoblotting (IB).
(C) In vitro 7SK RNA pull-down assay was performed, and the resultant pellet was analyzed by IB.
(D and E) JMJD6 and Brd4 interaction examined through in vitro GST pull-down assay (D) or IP in HEK293T cells (E). Note that JMJD6 undergoesmultimerization,
which is preserved even under denatured conditions.
(F) HEK293T cells transfected with control siRNA or two independent siRNAs specifically targeting JMJD6 or Brd4 were subjected to IB analysis.
(G and H) Pie chart showing genes regulated by JMJD6 (G) or Brd4 (H) assessed by Gro-seq analysis in cells as described in (F) (FDR < 0.001).
(I) Overlap between JMJD6- and Brd4-regulated genes from (G) and (H), respectively.
(J) Genes regulated in common and in the same direction by JMJD6 and Brd4.
See also Figures S1 and S2 and Tables S1, S2, S3, and S4.Brd4-transfected HEK293T cells. For the vast majority of genes,
Pol II occupancy was at a much higher density at the promoter-
proximal region compared to gene body (Figure S2F). We then
calculated the relative ratio of Pol II density in the promoter-prox-
imal region and the gene body, which has been termed as trav-
eling ratio (TR) (Reppas et al., 2006) or pausing index (Zeitlinger
et al., 2007) (Figure 2A). It was found that nearly 90% of Pol-II-
bound genes have a TR larger than 2, suggesting that these
genes experience promoter-proximal pausing regulation (Fig-C
ure S2G), a result similar to what was found in embryonic stem
(ES) cells (Rahl et al., 2010). When all Pol-II-bound genes were
assessed, JMJD6 exhibited only a modest, although significant,
effects on TR values, whereas the number of genes and the
magnitude of TR changes affected by Brd4 knockdown was
much larger (Figures 2B and 2C). However, when considering
only JB genes, we found that knockdown of either protein led
to a significant increase of TR values and the changes were in
a similar extent, suggesting that these factors coregulate Pol IIell 155, 1581–1595, December 19, 2013 ª2013 Elsevier Inc. 1583
Figure 2. JMJD6 and Brd4 Promote Promoter-Proximal Pol II Pause Release
(A) Schematic representation of the way applied to calculate Pol II traveling ratio (TR).
(B and D) Pol II TR distribution in HEK293T cells for all Pol-II-bound genes (B) or genes that are positively regulated in common by JMJD6 and Brd4 (n = 1,022)
(JB genes) (D).
(C and E) Box plots showing the change of Pol II TR caused by knockdown of JMJD6 orBrd4 in (B)–(D). (E) Median (C): 6.54 (siCTL), 10.36 (siBrd4), 7.48 (siJMJD6);
median (E): 2.61 (siCTL), 5.46 (siBrd4), 4.14 (siJMJD6).
(F) Gro-seq read distribution along the transcription units from 2 kb upstream of the transcription start site (TSS) to 2.5 kb downstream of the transcription
termination site (TTS) in HEK293T cells transfected with control, JMJD6, or Brd4 siRNA. Region included was normalized and scaled to 1.
(G and I) TR distribution based on Gro-seq analysis in HEK293T cells for all Pol-II-bound genes (G) or JB genes (I).
(H and J) Box plots showing change of TR caused by knockdown of JMJD6 or Brd4 as shown in (G)–(I). (J) Median (H): 0.61 (siCTL), 1.82 (siBrd4), 1.00 (siJMJD6);
median (J): 0.33 (siCTL), 1.22 (siBrd4), 0.66 (siJMJD6).
See also Figure S2.promoter-proximal pause release on these genes (Figures 2D
and 2E). Furthermore, the significance of the TR change caused
by JMJD6 or Brd4 knockdown was comparable to that by DRB
or flavopiridol treatment, two P-TEFb inhibitors (Figures S2H and
S2I). Specifically, 85% of those 1,022 genes showed an
increase of TR value after knocking down either JMJD6 or
Brd4 (Figure S2J). The fold change of TR value on a specific
gene correlated poorly with its length (Figures S2K and S2L).
To further strengthen the idea that both JMJD6 and Brd4 are
essential and function in a protein complex to regulate pause
release of JB genes, double knockdown of JMJD6 and Brd4
displayed no additive effects on TR change compared to knock-
down of JMJD6 or Brd4 individually (Figure S2M).
In further support of their role in promoting Pol II promoter-
proximal pause release, knockdown of JMJD6 or Brd4 caused1584 Cell 155, 1581–1595, December 19, 2013 ª2013 Elsevier Inc.a slight increase of read density at promoter-proximal region
but a dramatic decrease along the gene body based on Gro-
seq analysis, resembling a typical pause release defect (Fig-
ure 2F). By the criterion defining Pol II TR as the relative ratio of
Gro-seq reads density in the promoter-proximal region and the
gene body, both JMJD6 and Brd4 knockdown caused a signifi-
cantly increased TR compared to control samples when all Pol-
II-bound genes were examined, with the magnitude of TR
changes caused by Brd4 knockdown being more dramatic (Fig-
ures 2G and 2H). Importantly, 85% of those 1,022 genes
showed an increase of TR value after knocking down either
JMJD6 or Brd4 (Figures 2I, 2J, and S2N). Similar to analyses
based on Pol II ChIP-seq, the fold change of TR value assessed
by Gro-seq on a specific gene was poorly correlated with its
length (Figures S2O and S2P).
Genomic Localization of JMJD6 and Brd4
ChIP-seq profiling of JMJD6 and Brd4 binding sites across the
genome revealed that Brd4 localized on the promoter region of
a large set of genes (n = 6,120, 44% of its total binding sites),
with the remaining 56% (n = 7,878) located on intergenic and
intragenic regions (Figure 3A). In contrast, JMJD6 was detected
on only 500 promoters, comprising 6% of all JMJD6 binding
sites, with the vast majority of JMJD6 binding sites (n = 7,815)
located on intergenic and intragenic regions (Figures 3B and
S3A). Identified binding sites for JMJD6 and Brd4 were validated
by ChIP-qPCR (Figure S3B). Interestingly, JMJD6 and Brd4 were
highly correlated on distal regions (intergenic and intragenic
regions) (Figures 3C and S3C). Although Brd4 promoter occu-
pancy was observed on 53% of those JB genes, only 3%
of them (n = 34) had detectable peaks for JMJD6 (Figure 3D).
Indeed, the ChIP-seq tag density for JMJD6 was close to back-
ground at the promoter regions of those JB genes (Figures 3E
and 3F). These observations raised the intriguing possibility
that JMJD6, with Brd4, might regulate Pol II promoter-proximal
pause release for the subset of genes they jointly regulated in
an unexpected distal regulatory fashion, which would be most
likely established via long-range interactions between promoters
and JMJD6 and Brd4 co-occupied distal sites (Figure 7K).
Characterization of JMJD6 and Brd4 Co-Occupied
Distal Sites
To test whether JMJD6 and Brd4 cobound distal sites might
correspond to current definitions of enhancers, we performed
ChIP-seq for several histone marks and coactivators, finding
that they were enriched with H3K4me1/2, H3K27Ac, and P300
but exhibited low/no levels of H3K4me3, features characteristic
of active enhancers (Figures 3E and 3F). We hypothesized that
Brd4 recognition of acetylated histones was likely to account
for the recruitment of the Brd4 and JMJD6 complex to their
co-occupied enhancers because the two bromodomains of
Brd4 are well established to bind to acetylated histone tails,
mainly focusing on diacetylated H3 (K9 and K14) (H3Ac) or
tetraacetylated H4 (K5, 8, 12, and 16) (H4Ac). Indeed, 95% of
Brd4 binding regions and 90% of JMJD6 and Brd4 cobound
distal enhancers were enriched with either H3Ac or H4Ac marks
(Figures S3D, S3E, and 3E–3G). To support the requirement of
Brd4 for JMJD6 binding, it was found that JMJD6 binding
decreased significantly following knockdown of Brd4 on
randomly selected JMJD6 and Brd4 cobound distal enhancers
(Figure 3H); however, knockdown of JMJD6 exerted no signifi-
cant effects on Brd4 binding (Figure 3I).
H4R3me2(s) Demethylase Activity of JMJD6
To explore how the recruitment of the JMJD6 and Brd4 protein
complex to their co-occupied distal enhancers functionally links
to the regulation of Pol II promoter-proximal pause release, we
first examined JMJD6 histone demethylase activity. It was found
that, in contrast to the enzymatically dead mutant, wild-type
JMJD6 purified from bacterial cells specifically demethylated
methylated histone H4R3, includingmono- (H4R3me1), symmet-
ric di-(H4R3me2(s)), and asymmetric di-(H4R3me2(a)) forms, but
not other methylated arginine or lysine residues examined. Total
levels of histone H3 and H4 remained unchanged (Figures 4A,C
S3F, and S3G). An interacting ssRNA (Hong et al., 2010), its
sense or antisense form, was included in our demethylase assay,
finding that it exerted no effects on JMJD6 enzymatic activity
(Figure 4A). To examine JMJD6 regulation by posttranslational
modifications (PTMs) or functionally associated protein partners,
we performed in vitro histone demethylase assays by using Flag-
tagged JMJD6 or its enzymatically deadmutant (H187A) purified
from HEK293T cells following overexpression. Again, JMJD6
displayed a specific demethylase activity toward H4R3me, but
not H4K20me or other arginine or lysine methylations examined.
In contrast, the enzymatically dead JMJD6 mutant (H187A) had
no effect on any histone modifications examined (Figures 4B
and S3H; data not shown). RNaseA was also included in the
demethylation reactions to remove any RNA copurified with
the enzyme, finding that it had no effect on JMJD6 enzymatic
activities (Figure 4B). Furthermore, JMJD6 demethylase activity
toward H4R3me was confirmed using histone tail peptides as
substrates (Figure S3I).
As H4R3me2(s) and its methyltransferase, PRMT5, have been
suggested to associate with transcriptional repression, we
focused on the demethylase activity of JMJD6 toward this
histone mark in this current study (Wysocka et al., 2006; Xu
et al., 2010). To further support JMJD6 demethylase activity
toward H4R3me2(s), a significant change of H4R3me2(s) occu-
pancy was observed on JMJD6 and Brd4 cobound distal en-
hancers upon JMJD6 knockdown (Figures 4C and 4D), but not
on the promoter regions of those JB genes (Figure 4E). Because
histone modifications exert effects through recruiting ‘‘reader’’
proteins or noncoding RNAs (Lachner et al., 2003; Ruthenburg
et al., 2007; Yang et al., 2011), we speculated that JMJD6 deme-
thylation of the repressive H4R3me2(s) mark, whichmight be read
by 7SK snRNA andHEXIM1/2, would result in the disassembly of
the inhibitory complex imposed on P-TEFb complex. Probing
MODified Histone Peptide Array with purified HEXIM1 protein
revealed no specific binding to modified histone tails (data not
shown). Intriguingly, 7SK snRNA was found to associate with
several histone peptides on the array, with enrichment of
H4R3me2, as well as H4K5Ac, H4K8Ac, H4K12Ac, and
H4K16Ac modifications (Figures 4F, S3J, and S3K). In vitro
RNA pull-down confirmed that 7SK snRNA specifically asso-
ciated with nucleosomes enriched for H4R3me2 or H4Ac (K5,
8, 12, and 16), but not H3R2me2 or H3Ac (K9 and 14) (Figure 4G).
Furthermore, H4R3me2(s)-containing histone tails were found to
specifically associate with the 50-, but not 30-terminal half of 7SK
(Figures 4H and S3L). Together, these data suggest that JMJD6-
mediated demethylation of H4R3me2(s), a repressive histone
mark directly read by 7SK snRNA, can potentially result in the
dismissal of 7SK snRNA/HEXIM1 inhibitory complex and subse-
quent P-TEFb complex activation and transcriptional pause
release (Figure 7K).
A 7SK snRNA Decapping Function of JMJD6
7SK snRNA is capped posttranscriptionally through the addition
of a methyl group directly on the gamma-phosphate of its first 50
nucleotide by its capping enzyme, BCDIN3/MePCE (Jeronimo
et al., 2007). The cap structure enhances the stability of 7SK
snRNA by protecting the RNA from exonucleolytic degradation
(Jeronimo et al., 2007; Shumyatsky et al., 1990). As a recentell 155, 1581–1595, December 19, 2013 ª2013 Elsevier Inc. 1585
Figure 3. JMJD6 and Brd4 Genomic Binding
(A and B) Genomic distribution of Brd4 (A) or JMJD6 (B) binding sites.
(C) Heatmap representation of JMJD6 and Brd4 tag density centered on JMJD6 ChIP-seq peaks.
(D) Venn diagram showing the number of genes having JMJD6 and/or Brd4 binding on promoter regions among those JB genes.
(E) ChIP-seq tag distribution of JMJD6, Brd4, H3Ac, H4Ac, H3K4me3, H3K4me2, H3K4me1, H3K27Ac, or P300 surrounding TSS of those JB genes (left), the
center of JMJD6 and Brd4 cobound distal sites (middle), or all of its own binding sites in the genome (right).
(F) JMJD6, Brd4, H3Ac, H4Ac, H3K4me3, H3K4me2, H3K4me1, H3K27Ac, or P300 binding on selected genomic regions: C16orf93 or TRIM11 promoter region
and the nearby JMJD6 and Brd4 cobound distal enhancer (center of enhancer: chr16:30,733,200 [left]; chr1:226,633,061 [right]).
(G) Pie chart displaying the percentage of JMJD6 and Brd4 cobound distal sites with or without H4Ac or H3Ac marks.
(legend continued on next page)
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structural study suggested that methyl group on ssRNA might
serve as substrate of JMJD6 (Hong et al., 2010), we hypothe-
sized that JMJD6 might possess a novel activity toward the
methyl group in the cap structure of 7SK snRNA, which could
result in 7SK snRNA destabilization and subsequent P-TEFb
activation. Indeed, BCDIN3 efficiently methylated 7SK snRNA,
and the methylation signals decreased in a dose-dependent
manner in the presence of JMJD6 (Figures 4I and S3M). Further-
more, demethylation of 7SK snRNA by JMJD6 was dependent
on its JmjC domain (Figure S3N). Surprisingly, neither JMJD6
nor Brd4 knockdown resulted in a significant change of total
7SK snRNA levels assessed by northern blotting in cells,
suggesting JMJD6 demethylation of 7SK snRNA might occur
locally on chromatin (Figure S3O). 7SK snRNA ChIRP was then
performed using a single DNA oligonucleotide, which was shown
to specifically target and efficiently pull down 7SK snRNA (Yang
et al., 2001). Indeed, around 85% of total cellular 7SK snRNA
was retrieved, but not GAPDH mRNA (Figure 4J). Knockdown
of BCDIN3 led to a significant decrease of the tags of our identi-
fied 7SK binding peaks (p < 10E-100), further supporting speci-
ficity of the 7SK ChIRP. Consistent with our hypothesis, 7SK
snRNA occupancy increased significantly on JMJD6 and Brd4
cobound distal enhancers following JMJD6 or Brd4 knockdown,
but not on the promoter regions of those JB genes (Figures 4K
and S3P). Increased HEXIM1 binding was also observed for a
number of JMJD6 and Brd4 cobound distal enhancers tested
by conventional ChIP (Figure 4L). We therefore have coined a
presumptive designation for the JMJD6 andBrd4 cobound distal
enhancers, referring to them as anti-pause enhancers (A-PEs),
on which JMJD6 displays demethylation activity toward
H4R3me2(s) and methyl group in the 7SK snRNA cap.
Anti-Pause Enhancers Loop to and Regulate Pausing
Release of Target Gene Promoters
To test the hypothesis that JMJD6 regulation of Pol II promoter-
proximal pause release would be established via long-range
interactions between promoters and anti-pause enhancers
(A-PEs), chromosome conformation capture (3C) analysis was
performed for a number of genes, which were strongly regulated
by JMJD6 and Brd4, including SAMD11, ALDOA, RHOB,CHKB,
C16orf93, and TRIM11, all of which showed specific interactions
with their nearby cognate A-PEs (Figures 5A–5C and S4A–S4C).
Intriguingly, the detected interactions were generally not signifi-
cantly affected by either JMJD6 or Brd4, suggesting that they
were established based on other enhancer-bound factors,
regardless of gene expression status. The striking presence of
nine subunits of the mediator complex in our MS analysis for
proteins associated with JMJD6, including MED1 (Table S1),
co-occupancy of Brd4 with MED1 on enhancers and promoters
in several cancer cell lines, and mediators’ roles in functionally
connecting enhancers and core promoters of many active genes
prompted us to test whether MED1 affects looping formation(H and I) Brd4 is required for JMJD6 binding on chromatin, but not vice versa. Stan
HEK293T cells. The five regions bound by both JMJD6 and Brd4 tested were se
(±SEM, ***p < 0.001). (1:chr1:232,701,545–232,701,745; 2:chr4:12,251,121–12
chr7:61,371,401–61,371,601).
See also Figure S3.
C
between gene promoters and A-PEs (Kagey et al., 2010; Lovén
et al., 2013). Indeed, knockdown of MED1 impaired the looping
formation for all gene promoters and A-PEs tested (Figures
5A–5C and S4A–S4C).
To further demonstrate that A-PEs are functionally linked
to transcriptional control of these coding genes, selected pro-
moter regions were cloned with corresponding A-PEs into
pGL3 basic luciferase vectors and transfected into HEK293T
cells. For all ten constructs tested, the combination of promoter
sequence and anti-pause enhancer (P+A-PE) drove the lucif-
erase gene expression efficiently, which was impaired following
knockdown of either JMJD6 or Brd4 (Figures 5D–5F and S4D–
S4J, far right three columns). To support the notion that A-PEs
regulate transcription at the Pol II promoter-proximal pause
release step, Pol II ChIP analysis revealed that the relative ratio
of Pol II density in the promoter-proximal region and two
selected regions on the luciferase gene body increased signifi-
cantly following knockdown of JMJD6 or Brd4, suggesting a
defect in Pol II pause release (Figures 5G and 5H). Interestingly,
the luciferase reporter activities detected from vectors contain-
ing promoter sequences only (P), presumably lacking of 7SK
snRNA/HEXIM inhibitory complex associated with A-PEs, was
significantly lower than vectors containing both promoter se-
quences and A-PEs (P+A-PE), suggesting that JMJD6 and
Brd4 might have additional roles, such as retaining the P-TEFb
complex, besides their function in dismissing the inhibitory
7SK snRNA/HEXIM complex (Figures 5D–5F and S4D–S4J).
Consistent with this, the relative ratio of Pol II density in the
promoter-proximal region and selected region in the body of
luciferase gene detected from luciferase vector containing
promoter sequence only (P) was significantly larger than that
from luciferase vectors containing both promoter sequence
and A-PE (P+A-PE) (Figures 5G and 5H).
Activation of the P-TEFb Complex by JMJD6 and Brd4
Our data suggested that JMJD6 and Brd4 might retain and
activate the P-TEFb complex in addition to dismissing 7SK
snRNA/HEXIM. Because Brd4 is known to interact with the
Cyclin T1 in the P-TEFb complex and to be capable of extracting
the P-TEFb complex from 7SK snRNP (Jang et al., 2005; Krueger
et al., 2010; Yang et al., 2005), we investigated whether JMJD6
might play a similar role. JMJD6 was found to specifically
interact with CDK9, but not with Cyclin T1 (Figures 6A, 6B, and
S5A). Both the amino-terminal and the JmjC domain of JMJD6
were able to interact with CDK9, whereas carboxyl-terminal,
containing the unstructured region, failed to do so (Figures
S5B and S5C). The carboxyl-terminus (aa 315–372) of CDK9
was apparently required for its binding with JMJD6 as any trun-
cations lacking this region failed to bind (Figure S5D), but suffi-
ciency could not be tested because it alone was not expressed
in cells. Therefore, our data and those from previous studies
demonstrated that JMJD6 and Brd4 interact with distinctdard ChIP assay was performed with anti-JMJD6 (H) or anti-Brd4 (I) antibody in
lected from Figure S3B. ChIP signals were presented as percentage of inputs
,251,321; 3: chr18:2,832,201–2,832,401; 4: chr3:13,664,851–13,665,051; 5:
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Figure 4. H4R3me and 7SK snRNA Demethylase Activity of JMJD6
(A and B) Histone demethylase activity of JMJD6 examined by in vitro histone demethylase assay using JMJD6 protein purified from bacterial cells (A) or
overexpressed HEK293T cells (B).
(C and E) H4R3me2(s) ChIP-seq tag density distribution surrounding the center of JMJD6 and Brd4 cobound distal enhancers (C) or TSS of those JB genes (E).
(D) Box plot showing change of H4R3me2(s) occupancy in (C) is significant (median: 7.73 [siCTL], 14.52 [siJMJD6]).
(F) 7SK snRNA association with modified histone tails detected by Histone Peptide Array. Spot P20 serves as a positive control for IB with HRP-conjugated
streptavidin.
(G) 7SK snRNA pull-down mixing in vitro transcribed, biotinylated 7SK snRNA with purified mononucleosomes, followed by IB analysis.
(H) 7SK snRNA association with H4R3me2(s)-containing histone tails was examined by in vitro histone peptide pull-down assay. 50 or 30 7SK sequences were
incubated with or without H4R3me2(s)-containing histone tails. Northern blotting (N.B.) was performed with probes targeting 50 end (left) or 30 end (right) of 7SK
snRNA.
(I) JMJD6 demethylation of 7SK snRNA examined through in vitro demethylation assay. Equal amount of each reaction was prepared for dot blotting assay
followed by autoradiogram or IB with HRP-conjugated streptavidin.
(J) The percentage of cellular 7SK snRNA retrieved by ChIRP. GAPDH served as a negative control. Data were presented as percentage of inputs (±SEM)
(K) 7SK ChIRP tag density distribution surrounding the center of JMJD6 and Brd4 cobound distal enhancers.
(L) Standard ChIP assaywas performedwith anti-HA antibody in HEK293 cells stably expressingHA-taggedHEXIM1. ChIP signals were presented as percentage
of inputs (±SEM, **p < 0.01, ***p < 0.001). JMJD6 and Brd4 cobound distal region A: chr16:30,733,100–30,733,300 (Figure 3F, left); B: chr1:226,632,961–
226,633,161 (Figure 3F, right); C: chr1:829,973–830,173 (Figure 5A); D: chr16: 29,940,404–29,940,604 (Figure 5B); E: chr2:19,426,222–19,426,422 (Figure 5C); F:
chr22:49,429,007–49,429,207 (Figure S4A).
See also Figure S3.
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subunits in the P-TEFb complex, with JMJD6 interacting with
CDK9 and Brd4 with Cyclin T1. Furthermore, CDK9 was directly
released from the 7SK/HEXIM snRNP by both JMJD6 (1–305)
and Brd4 (1209–1362) (regions binding with the P-TEFb com-
plex) (Figure 6C).
To support the hypothesis that both JMJD6 and Brd4 are
required to efficiently retain and activate the P-TEFb complex,
knockdown of either JMJD6 or Brd4 caused a significant
decrease of CDK9 occupancy on the promoter regions as well
as gene bodies of those JB genes (Figures 6D–6G and S5F–
S5G), whereas the CDK9 protein levels remained unchanged
(Figure 1F). In accordance with the decrease of CDK9 occu-
pancy, Pol II ser2 phosphorylation decreased significantly
across those JB transcription units as well (Figures 6F–6H). We
therefore are tempted to suggest amodel in which the dual enzy-
matic activities of JMJD6 act locally to cause dismissal of the
7SK/HEXIM1 inhibitory complex, and the ability of both JMJD6
and Brd4 to retain P-TEFb leads to subsequent Pol II pro-
moter-proximal pause release (Figure 7K).
H4R3me2(s) Demethylation and 7SK Decapping/
Demethylation in JMJD6 and Brd4-Mediated Pol II
Promoter-Proximal Pause Release
If the dynamic regulation of the identified dual substrates of
JMJD6, H4R3me2(s) and 7SK g-methylphosphate cap, is critical
for the release of 7SK/HEXIM1 inhibitory complex imposed on
the P-TEFb complex, we would expect to see that knockdown
of their corresponding methyltransferases, PRMT5 and
BCDIN3/MEPCE, would result in enhanced Pol II promoter-prox-
imal pause release for those JB genes. However, the effect
would be expected to bemodest due to the fact that these genes
are already mostly transcriptionally active. Similar results would
also be expected from knocking down the inhibitory compo-
nents, 7SK snRNA and HEXIM1/2. Knockdown of PRMT5 in
HEK293T cells caused a further decrease of H4R3me2(s) levels
on A-PEs (Figures 7A, S6A, and S6B). To support our hypothesis,
we observed a significant, although modest, decrease of Pol II
TR after PRMT5 knockdown for JB genes (Figures 7B and 7J).
Gro-seq-based TR measurement also supported the inhibitory
function of PRMT5 in Pol II promoter-proximal pause release
(Figures 7C and 7D). To further strengthen the idea that JMJD6
and PRMT5 antagonize each other in transcriptional pause
release control, double knockdown of these two proteins
neutralized the TR changes caused by knocking down of each
protein individually (Figures 7B and 7J). Together, these data
reveal that a dynamic regulation of H4R3me2(s) specifically
occurring at A-PEs, with JMJD6 demethylase activity being
dominant, is critical for Pol II promoter-proximal pause control.
We next examined the role of decapping/demethylation of
7SK snRNA on Pol II promoter-proximal pause release by
knocking down BCDIN3 followed by Pol II ChIP-seq analysis
(Figures 7E and S6C). As expected, knockdown of BCDIN3
resulted in a significant decrease of 7SK snRNA level (Fig-
ure S6D). In support of a role of decapping/demethylation of
7SK snRNA on Pol II promoter-proximal pause release, similar
to what was observed for PRMT5, BCDIN3 knockdown led to
a significant, although modest, decrease of Pol II TR for those
JB genes (Figures 7F and 7J), which was confirmed by Gro-C
seq analysis (Figures 7G and 7H). Double knockdown of
JMJD6 and BCDIN3 neutralized the TR changes caused by
knocking down of each protein individually, indicating their
antagonistic functions (Figures 7F and 7J). In contrast, double
knockdown of PRMT5 and BCDIN3 caused an additive effect
on TR change, suggesting these two proteins function in parallel
to regulate pause release for those JB genes (Figures 7I and 7J).
Finally, based on Pol II ChIP-seq and Gro-seq analyses, both
7SK snRNA and HEXIM1/2 knockdown caused a significant,
although modest, decrease of TR, similar to what observed for
other inhibitory components, such as PRMT5 and BCDIN3 (Fig-
ures S6E–S6R).
Anti-Pause Enhancers in Other Cell Types
To investigate potential JMJD6 and Brd4 co-occupied anti-
pause enhancers in a second cell line, HeLa cells, Gro-seq
experiments were performed, and it was found that JMJD6
and Brd4 coregulated a substantial number of genes (n = 844).
Significantly, 96% of these genes required both proteins for acti-
vation (n = 814), which we referred as JB genes, representing
83% of the total genes positively regulated by JMJD6 (Figures
S7A–S7D). JMJD6 and Brd4 control of Pol II promoter-proximal
pause release was readily seen in HeLa cells for those JB genes
(Figures S7E and S7F). As was the case in HEK293T cells, Brd4
occupied both promoters and distal regions, whereas JMJD6
bound predominately to distal regions in HeLa cells (Figures
S7G and S7H). Importantly, JMJD6 and Brd4 were highly cor-
related on distal regions (Figures S7I and S7J). Only 13% of
those JB genes had detectable JMJD6 peaks on their promoter
regions, suggesting that JMJD6 regulates Pol II promoter-prox-
imal pause release based on the actions at distal sites (Figures
S7K and S7L).
To characterize JMJD6 and Brd4 cobound distal sites (anti-
pause enhancers), we performed ChIP-seq for H3Ac and H4Ac
and examined several data sets from the Encode project in
HeLa cells. It was found that, similar to our findings in
HEK293T cells, JMJD6 and Brd4 cobound distal sites repre-
sented active enhancers (enriched with H3K4me1/2 and
H3K27Ac, but exhibiting relatively low levels of H3K4me3) with
both H3Ac and H4Ac histone marks (Figure S7L). These data
suggest that anti-pause enhancer-associated JMJD6 and Brd4
regulation of Pol II promoter-proximal pause release occurs in
many cell types.
DISCUSSION
Brd4 and JMJD6 Regulate Promoter-Proximal Pause
Release
The evidence presented in this manuscript suggests that JMJD6
and Brd4, acting as functional partners, regulate Pol II promoter-
proximal pausing in a large subset of genes based on their
actions on distal enhancers, termed anti-pause enhancers
(A-PEs). Mechanistically, it appears that acetylated histone H4/
H3-mediated, Brd4-dependent binding of JMJD6, an enzyme
that displays dual demethylase activities toward both histone
arginine and the 7SK snRNA cap, on these A-PEs leads to the
release of 7SK snRNA/HEXIM1 inhibitory complex imposed on
P-TEFb. Meanwhile, both JMJD6 and Brd4 are capable ofell 155, 1581–1595, December 19, 2013 ª2013 Elsevier Inc. 1589
Figure 5. Anti-Pause Enhancers Are Functionally Connected to Coding Gene Promoters
(A–C) Interactions between selected promoter regions (P), SAMD11 (A), ALDOA (B), or RHOB (C) and anti-pause enhancers (A-PEs) detected by 3C analysis.
Interaction intensity was measured by qPCR using validated primers specific for the tested regions following 3C samples preparation. Data were presented as
fold enrichment over 3C samples without adding T4 ligase after normalization to input (±SEM, *p < 0.05, **p < 0.01, ***p < 0.001). A genomic region around 20 kb
from each A-PE served as a negative control (N). Center of enhancer: chr1:830,073 (A); chr16:29,940,504 (B); chr2:19,426,322 (C).
(D–F) Luciferase reporter activities driven by selected promoter sequences and A-PEs. HEK293T cells were transfected with control luciferase vector, luciferase
vector containing promoter sequence only (P), or both promoter sequence and its corresponding nearby A-PE (P+A), followed by luciferase activity measurement.
Data were normalized to Renilla internal control (±SEM, *p < 0.05, **p < 0.01, ***p < 0.001).
(legend continued on next page)
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Figure 6. Activation of the P-TEFb Complex
by JMJD6 and Brd4
(A and B) JMJD6 interaction with CDK9 (A) or
Cyclin T1 (B) examined by IP in HEK293T cells.
IgG, immunoglobulin G; H.C., IgG heavy chain.
(C) Release of the P-TEFb complex by JMJD6 or
Brd4 protein examined by in vitro P-TEFb release
assay.
(D) CDK9 ChIP-seq tag distribution surrounding
TSS of those JB genes in HEK293T cells.
(E) Box plot showing change of CDK9 occupancy
in (D) is significant (median: 61.39 [siCTL], 32.90
[siBrd4], 15.62 [siJMJD6]).
(F and G) The changes of CDK9 (top) or Pol II
ser2 phosphorylation (bottom) occupancy after
knocking down of JMJD6 or Brd4 were shown for
specific genes, as indicated.
(H) Metagenes showing average Pol II ser2 phos-
phorylation ChIP-seq signals across those JB
transcription units. Units are mean tags per bin for
160 bins across the transcribed region of each
gene with 2 kb upstream (40 bins of 50 bp each)
and 5 kb downstream flanking regions (100 bins of
50 bp each).
See also Figure S5.extracting and retaining the P-TEFb complex on chromatin, lead-
ing to its activation, promoter-proximal Pol II pause release, and
gene activation.
Brd4 is required for transcriptional activation of a large number
of genes, with many of them also requiring JMJD6 for gene acti-
vation. However, a large number of genes exhibiting promoter-
proximal pause regulation by Brd4 are independent of JMJD6
for activation. Indeed, the Brd4 interactome contains other func-
tional partners, such as NSD3, that, whereas not required for the
Pol II promoter-proximal pause release of those genes jointly(G and H) Relative ratio of Pol II density in the promoter-proximal region and selected region in the body of luc
control siRNA or siRNA specifically targeting JMJD6 or Brd4 in the presence of luciferase report vector conta
sequence and A-PE (P+A) followed by Pol II ChIP analysis. qPCR was performed with primers as indicated
whereas F2+R2 and F3+R3 targeting two distinct regions on luciferase gene body. Data were presented as re
0.001).
See also Figure S4.
Cell 155, 1581–1595, Deregulated by JMJD6 and Brd4 (data not
shown), may function for a distinct cohort
of genes, based on binding on either
promoter regions or distal enhancers
(Rahman et al., 2011). Similarly, JMJD6
can function independent on Brd4 in




In the current study, we have focused on
the function of JMJD6 demethylase
activity on H4R3me2(s), a repressive
histone mark, in promoting transcrip-
tional pause release. As JMJD6 alsoexhibited demethylase activity toward H4R3me2(a), a histone
mark associated with transcriptional activation (Li et al., 2010;
Wysocka et al., 2006; Yang et al., 2010), we envision a role of
JMJD6 in gene repression. Indeed, our Gro-seq analysis re-
vealed that a subset of genes was repressed by JMJD6.Whether
JMJD6 represses gene transcription based on its H4R3me2(a)
demethylase activity remains as an interesting question for
future investigation. Here, we have also uncovered a JMJD6
enzymatic activity targeting RNA methylation, which is specific
to the methyl group in the 7SK snRNA cap structure. Testingiferase gene. HEK293T cells were transfected with
ining promoter sequence only (P) or both promoter
, with primer set F1+R1 targeting promoter region,
lative ratio of Pol II density (±SEM, **p < 0.01, ***p <
cember 19, 2013 ª2013 Elsevier Inc. 1591
Figure 7. H4R3me2(s) Methylation and 7SK RNA Methylation in Its Cap Structure Are Involved in JMJD6 and Brd4-Mediated Pol II Promoter-
Proximal Pause Release
(A and E) HEK293T cells transfected with control siRNA or two independent siRNAs specifically targetingPRMT5 (A) orBCDIN3 (E) were subjected to IB analyses.
(B, F, and I) Pol II TR distribution for JB genes in HEK293T cells transfected with siRNA(s) as indicated. Note that experiments shown in (B), (F), and (I) and
Figure S2M were performed at the same time.
(C and G) TR distribution based on Gro-seq analysis for JB genes in HEK293T cells transfected with control siRNA or siRNA specifically targeting PRMT5 (C) or
BCDIN3 (G).
(legend continued on next page)
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whether other JmjC-domain-containing proteins target to other
types of methylation found on single-stranded RNA (ssRNA)
including m3U and N6A methylation will be of particular interest
for future studies. It is noteworthy that JMJD6 demethylase
activities toward both H4R3me2(a) and methyl group in the 7SK
snRNA cap structure occur locally on chromatin, suggesting
that other demethylases with similar activities might exist, which
is also consistent with the fact that, despite being born with
severe developmental defects, viable JMJD6 knockout mice
could be identified at birth (Böse et al., 2004; Kunisaki et al.,
2004; Li et al., 2003).
7SK snRNA: A Noncoding RNA Reading Histone Marks
Our data support the idea that 7SK snRNA/HEXIM/P-TEFb is
tethered to chromatin through 7SK snRNA recognition of the
H4R3me2(s) mark on A-PEs. JMJD6/Brd4 protein complex
erasure of H4R3me2(s) releases 7SK snRNA/HEXIM inhibition,
allowing local P-TEFb activation to occur. Reading of other
histonemarks on chromatin, by 7SK snRNA,may also contribute
to its function in transcriptional regulation. Indeed, a specific
locked nucleic acid (LNA) targeting 7SK dramatically affects
Pol II promoter-proximal pause release and transcription of a
large set of genes.
In conclusion, our studies here have revealed anti-pause
enhancers regulate Pol II promoter-proximal pause release, on
which: (1) JMJD6 and Brd4 binding is detected; (2) there is
enrichment of H4Ac and H3Ac marks, as well as classical active
enhancer marks; (3) release of 7SK snRNA/HEXIM inhibitory
complex occurs, in response to JMJD6 enzymatic activity tar-
geting both H4R3me2(s) and/or 7SK snRNA cap; and (4) looping
is formed with coding gene promoters, providing the apparent
architectural basis for their ability to regulate transcriptional
pause release events at promoters. A-PEs, therefore, apparently
are enhancers with a function in transcriptional pause release,
with their unique feature being cobound by both JMJD6 and
Brd4, and the associated molecular mechanisms.
EXPERIMENTAL PROCEDURES
siRNA Transfection, RNA Isolation, and qRT-PCR
Two independent siRNAs against JMJD6, Brd4, PRMT5, BCDIN3,
HEXIM1, or HEXIM2 were used in this study (see Extended Experimental
Procedures for siRNA sequence information). Locked nucleic acid (LNA)
targeting 7SK snRNA was designed and purchased form Exiqon
(G*A*G*A*G*C*T*T*G*T*T*T*G*G*A*G [* = phosphorothioate]). siRNA and
LNA transfections were performed using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol. Transfection efficiency was deter-
mined by immunoblotting and/or qRT-PCR. Total RNA was isolated from(D and H) Box plots showing that the change of Pol II TR caused by knockdown of
1.30 (siPRMT5); median (J): 1.33 (siCTL), 1.01 (siPRMT5).
(J) Box plot showing change of Pol II TR as shown in (B), (F), and (I). Med
(siJMJD6+siPRMT5), 6.35 (siJMJD6+siBCDIN3), 2.86 (siPRMT5+siBCDIN3).
(K) (Model) regulation of transcriptional pause release of a subset of transcriptio
snRNA/HEXIM-associated inactive P-TEFb complex was tethered to chromatin t
recruitment of JMJD6/Brd4 protein complex exhibits dual enzymatic activities, bo
activity targeting 7SK snRNA methyl group in its cap structure, resulting in the
Meanwhile, the ability of both JMJD6 and Brd4 to interact with P-TEFb complex re
transcriptional elongation.
See also Figures S6 and S7.
C
HEK293T cells using RNeasy Mini Kit (QIAGEN) following the manufacturer’s
protocol. First-strand cDNA synthesis from total RNA was carried out using
SuperScript III First-strand cDNA synthesis system (Invitrogen). Resulting
cDNA was then analyzed by quantitative PCR (qPCR) using Stratagene
Mx3000 machine. Primers are specific for genes tested and their sequences
are available upon request. All qRT-PCRs were repeated at least three times,
and representative results are shown.
Traveling Ratio Calculation
Pol II TR was defined as the relative ratio of Pol II density in the promoter-
proximal region and the gene body. The promoter proximal region refers to
the window from 50 to +300 bp surrounding transcription start site (TSS).
Gene body is from 300 bp downstream of TSS to the annotated end. TR calcu-
lated based onGro-seq tag density was defined as ratio of Gro-seq reads den-
sity at the promoter-proximal bin (from 50 to +300 bp surrounding TSS) to
Gro-seq density at the gene body bin (from +300 bp to the annotated end).
The significance of the change of TR between control and knockdown samples
was displayed using box plot and determined using Student’s t test.
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